Novel Synthetic Biology-Based ADCC Technology
Assignee1Globe Biomedical Co., Ltd.
InventorsCHIANG J. LI, SHYAM UNNIRAMAN
Life of this patent
Estimating the term…
Abstract
A novel synthetic biology-based ADCC technology is provided that enhances or enables ADCC response. The novel ADCC technology can be used to prevent or treat cancers, infectious, inflammatory or autoimmune diseases, and other diseases where elimination of diseased cells is desirable.
Claims25
A genetic construct that encodes a transmembrane chimeric receptor comprising an ectodomain having a higher binding affinity to the Fc of an antibody than that of human CD16, a transmembrane domain, and an endodomain for mediating ADCC activation and amplification.
A transmembrane chimeric receptor comprising an ectodomain having a higher binding affinity to the Fc of an antibody than that of human CD16, a transmembrane domain, and an endodomain for mediating ADCC activation and amplification.
An immune effector cell infected or transfected ex vivo with a genetic construct that encodes a transmembrane chimeric receptor comprising an ectodomain having a higher binding affinity to the Fc of an antibody than that of human CD16, a transmembrane domain, and an endodomain for mediating ADCC activation and amplification.
(canceled)
(canceled)
Dependencies are inferred from the claim text.